|Mr. Grigorios Siokas||Chairman & CEO||N/A||N/A||1965|
|Mr. Georgios Terzis||Chief Financial Officer||44.64k||N/A||1982|
|Mr. Pavlos Ignatiades||COO & Director||N/A||N/A||1963|
|Mr. Peter Joseph Goldstein||Exec. Director||N/A||N/A||1963|
|Mr. Demetrios G. Demetriades||Sec. & Independent Director||N/A||N/A||1966|
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications, and medical devices with EU distribution network. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes and has a network of clients in Germany, the United Kingdom, the United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, the Netherlands, and Greece, as well as has distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, the United Kingdom. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
Cosmos Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.